Last reviewed · How we verify
Tenuate (DIETHYLPROPION)
At a glance
| Generic name | DIETHYLPROPION |
|---|---|
| Sponsor | ANI Pharmaceuticals |
| Drug class | Sympathomimetic Amine Anorectic |
| Target | Sodium-dependent dopamine transporter |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1959 |
Approved indications
- Obesity
Common side effects
- Valvular heart disease
- Pulmonary hypertension
- Bone marrow depression
- Agranulocytosis
- Leukopenia
- Convulsive episodes
- Psychotic episodes
- Dyskinesia
- Blurred vision
- Overstimulation
- Nervousness
- Restlessness
Drug interactions
- isocarboxazid
- pargyline
- phenelzine
- tranylcypromine
Key clinical trials
- A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- Anti-obesity Pharmacotherapy and Inflammation
- LOSS- Louisiana Obese Subjects Study (PHASE4)
- Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenuate CI brief — competitive landscape report
- Tenuate updates RSS · CI watch RSS
- ANI Pharmaceuticals portfolio CI